Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05313009 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | terminated | Phase 1 / Phase 2 | 5 | Medical University of South CarolinaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT04549428 |
| Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC |
| terminated |
| Phase 2 |
| 12 |
| Oncology Institute of Southern SwitzerlandOTHER |
| 1 |
| Nov 18, 2025 |
| clinicaltrials |
| NCT04396535 | Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05469178 | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | terminated | Phase 1 / Phase 2 | 26 | BerGenBio ASAINDUSTRY | 7 | Oct 29, 2025 | clinicaltrials |
| NCT04926831 | Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC(Geometry-N) | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04914897 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | terminated | Phase 2 | 106 | SanofiINDUSTRY | 11 | Oct 2, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT05662670 | A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 14 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05577715 | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 4, 2025 | clinicaltrials |
| NCT05245071 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA(CARMEN-LC06) | terminated | Phase 2 | 22 | SanofiINDUSTRY | 7 | Aug 29, 2025 | clinicaltrials |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 243 | GlaxoSmithKlineINDUSTRY | 12 | Aug 8, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT05617313 | Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | terminated | Phase 2 | 21 | Jeffrey ClarkeINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05691829 | Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC(IRRADIATE-Lung) | terminated | Phase 2 | 19 | NYU Langone HealthOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT03087708 | Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | terminated | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03777124 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04820023 | Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | terminated | Phase 1 / Phase 2 | 45 | Bridge Biotherapeutics, Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT03505710 | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer(DESTINY-Lung01) | terminated | Phase 2 | 181 | Daiichi SankyoINDUSTRY | 5 | May 30, 2025 | clinicaltrials |
| NCT04441138 | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC(ESR1814205) | terminated | Phase 2 | 10 | Rush University Medical CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT02093962 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 265 | ImmunoGenesisINDUSTRY | 10 | May 16, 2025 | clinicaltrials |
| NCT02521051 | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 11 | Massachusetts General HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05275673 | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | Faeth TherapeuticsINDUSTRY | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04892472 | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer(KEYNOTE B36) | terminated | Phase 2 | 15 | NovoCure GmbHINDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04925986 | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | terminated | Phase 2 | 9 | Sarah GoldbergOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06094296 | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT04512430 | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | terminated | Phase 2 | 4 | Fundación GECPOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | terminated | Phase 2 | 16 | Incyte CorporationINDUSTRY | 5 | Mar 13, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT04032847 | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | terminated | Phase 1 / Phase 2 | 27 | Achilles Therapeutics UK LimitedINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT00503971 | Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. | terminated | Phase 1 / Phase 2 | 33 | Spanish Lung Cancer GroupOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03496766 | Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS | terminated | Phase 2 | 9 | Spanish Lung Cancer GroupOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04495894 | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma | terminated | Phase 2 | 68 | Emory UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | terminated | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03705403 | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study(IMMUNOSABR2) | terminated | Phase 2 | 88 | Maastricht University Medical CenterOTHER | 6 | Jan 30, 2025 | clinicaltrials |
| NCT04856176 | A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | terminated | Phase 2 | 5 | Tufts Medical CenterOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04515979 | Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects | terminated | Phase 2 | 11 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 16, 2025source: clinicaltrials